Healan, Amanda M.B.
Mayo Clinic
Independent Science Writer and Editor Nashville Tennessee USA
Citations 1
The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives
Weber, Christopher J., Carrillo, María C. , Jagust, William J. , Shaw, Leslie M. , Trojanowski, John Q. , Saykin, Andrew J. , Sur, Cyrille, Méndez, Patricio Chrem, Li, Kuncheng , Iwatsubo, Takeshi , Perrin, Richard J. , Morris, John C. , Healan, Amanda M.B., Weiner, Michael W. , Saykin, Andrew J , Morris, John C , Jack, Clifford R. , Beckett, Laurel , Rao, Naren Prahalada , Black, Sandra E. , Chang, Chiung‐Chih , Sosa, Ana Luisa , Rowe, Christopher Cleon , Hall, Stephen E.
Alzheimer's & Dementia: Translational Research & Clinical Interventions | December 31, 2021 | Volume: 7 | Issue: 1 | Pages: No page available
Abstract The Worldwide Alzheimer's Disease Neuroimaging Initiative (WW‐ADNI) is a collaborative effort to investigate imaging and biofluid markers that can inform Alzheimer's disease treatment trials. It is a public‐private partnership that spans North America, Argentina, Australia, Canada, China, Japan, Korea, Mexico, and Taiwan. In 2004, ADNI researchers began a naturalistic, longitudinal study that continues today around the globe. Through several successive phases (ADNI‐1, ADNI‐GO, ADNI‐2, and ADNI‐3), the study has fueled amyloid and tau phenotyping and refined neuroimaging methodologies. WW‐ADNI researchers have successfully standardized analyses and openly share data without embargo, providing a rich data set for other investigators. On August 26, 2020, the Alzheimer's Association convened WW‐ADNI researchers who shared updates from ADNI‐3 and their vision for ADNI‐4.